Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

Subject Population (Pilot study) Inclusion Criteria: 1. Women with singleton, low-risk pregnancies 2. Gravida 1 (first pregnancy); or Gravida 2 (second pregnancy with first pregnancy carried to term or miscarried prior to 14 weeks or terminated); or Gravida 3 (third pregnancy with first and second pregnancies carried to term or one previous pregnancy carried to term and the other previous pregnancy miscarried prior to 14 weeks or terminated) 3. Ultrasound confirmed pregnancy dating prior to 14 weeks gestation 4. Non-obese (BMI 18.5-29.9 kg/M2) or Obese (Class I BMI 30-34.9 kg/M2 or Class II BMI 35-39.9 kg/M2) based on pregravid BMI Exclusion Criteria: 1. Known fetal chromosome abnormality, structural malformation or syndromes in current pregnancy 2. Tobacco or alcohol or drug use in current pregnancy 3. Pre-existing autoimmune conditions or other maternal chronic diseases like renal diseases, chronic hypertension, thrombophilia, type I or II diabetes or any vasculopathy 4. History of sickle cell anemia or sickle cell trait 5. High risk for gestational hypertension, pre-eclampsia, HELLP syndrome, fetal growth restriction (FGR), abruptio placentae secondary to hypertension or pre-eclampsia, stillbirth/intrauterine fetal death Subject Population (Main study) Inclusion Criteria Control Group: 1. Non-obese (pregravid BMI 18.5-29.9 Kg/M2)25 (N=80) 2. Women with singleton, low-risk pregnancies 3. Gravida 1 (first pregnancy); or Gravida 2 (second pregnancy with first pregnancy carried to term or miscarried prior to 14 weeks or terminated); or Gravida 3 (third pregnancy with first and second pregnancies carried to term or one previous pregnancy carried to term and the other previous pregnancy miscarried prior to 14 weeks or terminated) 4. Ultrasound-confirmed pregnancy dating prior to 14 weeks gestation 5. Gestational age at screening prior to 16 weeks Study Group: 1. Obese (pregravid Class I BMI 30-34.9 kg/M2 or pregravid Class II BMI 35-39.9 kg/M2) (N=80) 2. Women with singleton, low-risk pregnancies 3. Gravida 1 (first pregnancy); or Gravida 2 (second pregnancy with first pregnancy carried to term or miscarried prior to 14 weeks or terminated); or Gravida 3 (third pregnancy with first and second pregnancies carried to term or one previous pregnancy carried to term and the other previous pregnancy miscarried prior to 14 weeks or terminated) 4. Ultrasound confirmed pregnancy dating prior to 14 weeks gestation 5. Gestational age at screening prior to 16 weeks Exclusion Criteria Control and Study Groups: 1. Known fetal chromosome abnormality, structural malformation or syndromes in current pregnancy 2. Tobacco/alcohol/drug use in current pregnancy 3. Pre-existing autoimmune conditions or other maternal chronic diseases like renal diseases, chronic hypertension, thrombophilia, type I or II diabetes or any vasculopathy 4. History of sickle cell anemia or sickle cell trait 5. High risk for gestational hypertension, pre-eclampsia, HELLP syndrome, fetal growth restriction (FGR), abruptio placentae secondary to hypertension or pre-eclampsia, stillbirth/intrauterine fetal death a. The determination of whether or not the subjects are considered high risk for the conditions described above will be based on medical and obstetrical history review by clinical investigators with expertise in Maternal Fetal Medicine. 6. Contraindications to MRI (such as claustrophobia, metallic implant, etc.) based on MRI Screening 7. Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial 8. Any physical or psychological symptom, based on the clinical judgment of the study physician that would make a participant unsuitable for the study.